Aspen Neuroscience, Inc. (ASPE) company profile
ASPENasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.00−0.23 (-1.88%)
Close on Nov 17, 2026Market cap –P/E –Yield –
About Aspen Neuroscience
Pharmaceutical Preparations, SIC 2834
Aspen Neuroscience, Inc. is listed on Nasdaq under the ticker ASPE, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31.
Company profile
Company
- Legal name
- Aspen Neuroscience, Inc.
- Headquarters
- San Diego, CA
- Address
- 10835 Road To The Cure, Suite 100 92121
- Phone
- (858) 263-1222
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- ASPE
- Exchange
- Nasdaq
- IPO date
- Oct 30, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2124080
- CUSIP
- 044933109
- ISIN
- US0449331091
- FIGI
- BBG00PK9THH5
- Share class FIGI
- BBG00PK9THJ3
- EIN
- 83-1312969
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Faheem Hasnain | Executive Chair, Director | 384,679 |
| Damien McDevitt | See Remarks, Director | 561,648 |
| Dalen Meeter | Chief Financial Officer | – |
| Lisa Johnson-Pratt | Chief Commercial Officer | – |
| Kim Raineri | Chief Technology Officer | – |
| Jeffrey Lee Boerneke | General Counsel and Secretary | – |
| Capital GP VII LLC OrbiMed | Director | – |
| Peter A. Thompson | Director | 3,589,132 |
| Advisors Llc Orbimed | Director | 3,589,132 |
| Andrew Spaventa | Director | 308,076 |
| Thomas O. Daniel | Director | – |
| Caryn Peterson | Director | – |
| Cynthia Dorothy Perettie | Director | – |
| Douglas Carl Fisher | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 30, 2026
- Offer price
- $15.00
- Securities offered
- 9,375,000
- Gross proceeds
- $140.63M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Apr 28, 2027
“The initial public offering price is $15.00 per share .”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 30, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 29, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?